CAMELLIA-TIMI 61

CAMELLIA-TIMI 61 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

MAIN RESULTS:
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

N Engl J Med. 2018 Sep 20;379(12):1107-1117.

PRESENTATIONS

Primary Results (Bohula, ESC 2018)
Metabolic Slides (Scirica, EASD 2018)
Renal Outcomes (Bohula, AHA 2018)
Predictive value of echocardiographic markers of diastolic dysfunction for heart failure in overweight and obese patients in CAMELLIA-TIMI 61 (Gong, AHA 2021)
Assessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus (Berg, ACC 2022)
NT-proBNP, Body Mass Index, and Heart Failure Risk in CAMELLIA-TIMI 61 (Patel, ACC 2023)
Risk Of Kidney Disease Progression And Efficacy Of SGLT2 Inhibition In Patients With Type 2 Diabetes Mellitus (Moura, ACC 2023)

OTHER PUBLICATIONS

Design and Rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) Trial. Am Heart J. 2018 Aug;202:39-48.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018 Nov 24;392(10161):2269-2279.

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 Jan 15;139(3):366-375.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16;143(7):685-695.

Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. JACC. 2023;25:2391-2402.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2023 Oct 1;46(10):1807-1815.